Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases

Leptomeningeal metastases (LM) occur in 3–5% of patients with advanced non-small-cell lung cancer (NSCLC) and are associated with a dismal prognosis. We report three cases of NSCLC with LM who were treated with the combination of nimotuzumab and erlotinib. Magnetic Resonance Imaging (MRI) evaluation...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hongyu, Zhou, Lin, Lu, You, Su, Xiaomei, Cheng, Peng, Li, Dong, Gao, Hui, Li, Hua, Yuan, Weiwei, Zhang, Ling, Zhang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982442/
https://www.ncbi.nlm.nih.gov/pubmed/32021306
http://dx.doi.org/10.2147/OTT.S230399
_version_ 1783491311828992000
author Xu, Hongyu
Zhou, Lin
Lu, You
Su, Xiaomei
Cheng, Peng
Li, Dong
Gao, Hui
Li, Hua
Yuan, Weiwei
Zhang, Ling
Zhang, Tao
author_facet Xu, Hongyu
Zhou, Lin
Lu, You
Su, Xiaomei
Cheng, Peng
Li, Dong
Gao, Hui
Li, Hua
Yuan, Weiwei
Zhang, Ling
Zhang, Tao
author_sort Xu, Hongyu
collection PubMed
description Leptomeningeal metastases (LM) occur in 3–5% of patients with advanced non-small-cell lung cancer (NSCLC) and are associated with a dismal prognosis. We report three cases of NSCLC with LM who were treated with the combination of nimotuzumab and erlotinib. Magnetic Resonance Imaging (MRI) evaluation during follow-up showed significant improvement in cancer symptoms and decreased tumor size in all three patients. Grade 3 and 4 toxicities were rarely seen. Based on apparent efficacy of the regimen and fewer side effects, we suggest that nimotuzumab in combination with erlotinib may be a promising option for the treatment of NSCLC with LM.
format Online
Article
Text
id pubmed-6982442
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-69824422020-02-04 Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases Xu, Hongyu Zhou, Lin Lu, You Su, Xiaomei Cheng, Peng Li, Dong Gao, Hui Li, Hua Yuan, Weiwei Zhang, Ling Zhang, Tao Onco Targets Ther Case Series Leptomeningeal metastases (LM) occur in 3–5% of patients with advanced non-small-cell lung cancer (NSCLC) and are associated with a dismal prognosis. We report three cases of NSCLC with LM who were treated with the combination of nimotuzumab and erlotinib. Magnetic Resonance Imaging (MRI) evaluation during follow-up showed significant improvement in cancer symptoms and decreased tumor size in all three patients. Grade 3 and 4 toxicities were rarely seen. Based on apparent efficacy of the regimen and fewer side effects, we suggest that nimotuzumab in combination with erlotinib may be a promising option for the treatment of NSCLC with LM. Dove 2020-01-21 /pmc/articles/PMC6982442/ /pubmed/32021306 http://dx.doi.org/10.2147/OTT.S230399 Text en © 2020 Xu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Series
Xu, Hongyu
Zhou, Lin
Lu, You
Su, Xiaomei
Cheng, Peng
Li, Dong
Gao, Hui
Li, Hua
Yuan, Weiwei
Zhang, Ling
Zhang, Tao
Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
title Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
title_full Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
title_fullStr Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
title_full_unstemmed Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
title_short Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases
title_sort dual targeting of the epidermal growth factor receptor using combination of nimotuzumab and erlotinib in advanced non-small-cell lung cancer with leptomeningeal metastases: a report of three cases
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6982442/
https://www.ncbi.nlm.nih.gov/pubmed/32021306
http://dx.doi.org/10.2147/OTT.S230399
work_keys_str_mv AT xuhongyu dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases
AT zhoulin dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases
AT luyou dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases
AT suxiaomei dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases
AT chengpeng dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases
AT lidong dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases
AT gaohui dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases
AT lihua dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases
AT yuanweiwei dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases
AT zhangling dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases
AT zhangtao dualtargetingoftheepidermalgrowthfactorreceptorusingcombinationofnimotuzumabanderlotinibinadvancednonsmallcelllungcancerwithleptomeningealmetastasesareportofthreecases

Ejemplares similares